TABLE 3.
Population pharmacokinetic parameters of valganciclovir and bootstrap resultsa
| Parameter | Full data set |
Bootstrap analysis (n = 500) |
||
|---|---|---|---|---|
| Final estimate | RSE (%) | Median | 95% confidence interval | |
| CL (liters/h) = θ1 × FRENAL × FBSA/CL × FGENDER/CL | ||||
| θ2 | 9.07 | 3.7 | 9.04 | 8.36, 9.80 |
| FRENAL = (creatinine concentration/72.5)θ8 | ||||
| θ8 | −0.768 | 7.6 | −0.765 | −0.98, −0.63 |
| FBSA/CL = (BSA)θ9 | ||||
| θ9 | 1.31 | 8.5 | 1.32 | 1.07, 1.57 |
| FGENDER/CL = θ11GENDER | ||||
| θ11 | 1.15 | 4.3 | 1.16 | 1.06, 1.26 |
| V1 (liters) = θ2 × FBSA/V × FGENDER/V | ||||
| θ2 | 45.0 | 3.3 | 44.9 | 41.6, 48.0 |
| FBSA/V = (BSA)θ7 | ||||
| θ7 | 1.28 | 5.0 | 1.28 | 1.16, 1.42 |
| FGENDER/V = θ10GENDER | ||||
| θ10 | 1.14 | 3.9 | 1.14 | 1.06, 1.22 |
| Q (liters/h) = θ3 | ||||
| θ3 | 1.46 | 13.6 | 1.50 | 1.13, 2.20 |
| V2 (liters) = θ4 | ||||
| θ4 | 18.5 | 17.9 | 18.4 | 14.0, 30.9 |
| ka (h−1) = θ5 | ||||
| θ5 | 6.96 | 16.2 | 7.11 | 5.29, 11.00 |
| ALAG (h) = θ6 | ||||
| θ6 | 0.86 | 1.9 | 0.86 | 0.83, 0.91 |
| Interindividual variability (%) | ||||
| ωCL | 16.0 | 36.0 | 14.9 | 7.0, 20.7 |
| ωV1 | 9.3 | 51.0 | 8.7 | 0.7, 12.8 |
| ωV2 | 54.6 | 101.7 | 49.5 | 0.5, 128.9 |
| ωka | 59.2 | 79.2 | 58.7 | 0.7, 93.9 |
| IOV (%) | ||||
| IOVCL | 14.4 | 24.4 | 14.4 | 10.7, 18.3 |
| IOVka | 111.4 | 20.4 | 111.4 | 91.7, 135.6 |
| IOVV2 | 77.2 | 51.0 | 74.1 | 0.5, 113.2 |
| Residual variability, σP | 23.5 | 11.6 | 23.3 | 20.5, 25.7 |
a
RSE, relative standard error; IOV, interoccasion variability.